report.object
AI agents for clinical trials and regulatory operations
Expert-reviewed from public records, platform data, primary sources, and private research beyond AI search. Use /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/sample before purchase, then download PDF, JSON, or Markdown after checkout.
page.markdown
AI agents for clinical trials and regulatory operations.md
# AI agents for clinical trials and regulatory operations
Clinical-trial and regulatory-operations AI agents should be evaluated by the handoff they improve: accepted trial match, closed EDC query, inspection-ready eTMF document, clean registry/results update, usable endpoint record, safety-narrative QC or agency-response package.
## Object
| field | value |
| ---------------- | --------------------------------------------------- |
| report_id | RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS |
| schema_version | 2026-05-28 |
| last_updated_at | 2026-06-01 |
| category | AGENTS |
| sector | Life sciences |
| region | GLOBAL |
| confidence_score | 0.85 |
| source_count | 20 |
| evidence_count | 24 |
## Endpoints
| action | endpoint |
| ------------ | ------------------------------------------------------------------------------ |
| summary | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS |
| sample | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/sample |
| schema | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/schema |
| quote | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/quote |
| purchase | /checkout/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS?view=agent |
| versions | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/versions |
| changelog | /api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/changelog |
| monitor | /api/v1/monitors?report_id=RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS |
| mcp_resource | colophon://reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/sample |
## Coverage
| field | value |
| -------------- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| category | AGENTS |
| sector | Life sciences |
| region | GLOBAL |
| topics | clinical trial AI, regulatory operations, trial matching, protocol operations, monitoring, submissions, safety narratives, GCP, ICH E6(R3), ClinicalTrials.gov |
| source_classes | gcp_guideline, fda_guidance, regulatory_guidance, registry_docs, clinical_platform_docs, trial_matching_docs, regulation, enforcement_tracker, protocol_standard, data_standard, implementation_guide, safety_standard, submission_standard, vendor_directory |
| update_cadence | Weekly |
## Sample JSON
```json
{
"report_id": "RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS",
"slug": "ai-agents-clinical-trials-regulatory-operations",
"schema_version": "2026-05-28",
"title": "AI agents for clinical trials and regulatory operations",
"abstract": "Clinical-trial and regulatory-operations AI agents should be evaluated by the handoff they improve: accepted trial match, closed EDC query, inspection-ready eTMF document, clean registry/results update, usable endpoint record, safety-narrative QC or agency-response package.",
"category": "AGENTS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"clinical trial AI",
"regulatory operations",
"trial matching",
"protocol operations",
"monitoring",
"submissions",
"safety narratives",
"GCP",
"ICH E6(R3)",
"ClinicalTrials.gov"
],
"last_updated_at": "2026-06-01T00:00:00Z",
"source_count": 20,
"evidence_count": 24,
"confidence_score": 0.85,
"web_url": "/r/ai-agents-clinical-trials-regulatory-operations/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS",
"sample_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/sample",
"inventory_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/inventory",
"full_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/full",
"schema_endpoint": "/api/v1/reports/RPT_LIFE_SCIENCES_AI_AGENTS_CLINICAL_TRIALS_REG_OPS/schema",
"redaction": {
"status": "sample",
"paid_sections_redacted": true,
"preview_limits": [
"summary",
"table_of_contents",
"evidence_profile"
]
},
"coverage": {
"category": "AGENTS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"clinical trial AI",
"regulatory operations",
"trial matching",
"protocol operations",
"monitoring",
"submissions",
"safety narratives",
"GCP",
"ICH E6(R3)",
"ClinicalTrials.gov"
],
"source_classes": [
"gcp_guideline",
"fda_guidance",
"regulatory_guidance",
"registry_docs",
"clinical_platform_docs",
"trial_matching_docs",
"regulation",
"enforcement_tracker",
"protocol_standard",
"data_standard",
"implementation_guide",
"safety_standard",
"submission_standard",
"vendor_directory"
]
},
"confidence": {
"overall_confidence": 0.85,
"source_quality": 0.88,
"source_recency": 0.87,
"source_density": 0.83,
"claim_verifiability": 0.84,
"geographic_coverage": 0.8,
"known_gaps": [
"Regulatory and GCP sources define controls well, but vendor-specific agent performance is less public.",
"Trial matching evidence is often site, indication and EHR-specific.",
"Submission and safety narrative productivity claims rarely include inspection-ready audit records."
]
},
"document": {
"object": "report_document",
"schemaVersion": "2026-05-28",
"title": "AI agents for clinical trials and regulatory operations",
"subtitle": "The margin is fewer defects, not faster trial drafting.",
"abstract": "Clinical-trial and regulatory-operations AI agents should be evaluated by the handoff they improve: accepted trial match, closed EDC query, inspection-ready eTMF document, clean registry/results update, usable endpoint record, safety-narrative QC or agency-response package.",
"category": "AGENTS",
"sector": "Life sciences",
"region": "GLOBAL",
"topics": [
"clinical trial AI",
"regulatory operations",
"trial matching",
"protocol operations",
"monitoring",
"submissions",
"safety narratives",
"GCP",
"ICH E6(R3)",
"ClinicalTrials.gov"
],
"sources": [
{
"id": "S1",
"label": "ICH - E6(R3) Good Clinical Practice",
"publisher": "ICH",
"sourceClass": "gcp_guideline",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf",
"transformChain": [],
"url": "https://database.ich.org/sites/default/files/ICH_E6%28R3%29_Step4_FinalGuideline_2025_0106.pdf"
},
{
"id": "S2",
"label": "FDA - Digital Health Technologies for Remote Data Acquisition in Clinical Investigations",
"publisher": "FDA",
"sourceClass": "fda_guidance",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations",
"publicationDate": "2023-12-22",
"transformChain": [],
"provenanceNotes": "Guidance source; verify local applicability before relying on exact obligations.",
"url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/digital-health-technologies-remote-data-acquisition-clinical-investigations"
},
{
"id": "S3",
"label": "EMA - Computerised systems and electronic data in clinical trials",
"publisher": "EMA",
"sourceClass": "regulatory_guidance",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-electronic-data-clinical-trials_en.pdf",
"publicationDate": "2023-03-09",
"transformChain": [],
"provenanceNotes": "Guidance source; verify local applicability before relying on exact obligations.",
"url": "https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/guideline-computerised-systems-electronic-data-clinical-trials_en.pdf"
},
{
"id": "S4",
"label": "ClinicalTrials.gov - news and modernization updates",
"publisher": "National Library of Medicine",
"sourceClass": "registry_docs",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://clinicaltrials.gov/about-site/new",
"transformChain": [],
"url": "https://clinicaltrials.gov/about-site/new"
},
{
"id": "S5",
"label": "FDA - AI to support regulatory decision-making for drugs and biological products",
"publisher": "FDA",
"sourceClass": "fda_guidance",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological",
"transformChain": [],
"provenanceNotes": "Guidance source; verify local applicability before relying on exact obligations.",
"url": "https://www.fda.gov/regulatory-information/search-fda-guidance-documents/considerations-use-artificial-intelligence-support-regulatory-decision-making-drug-and-biological"
},
{
"id": "S11",
"label": "FDA - Electronic systems, electronic records and electronic signatures in clinical investigations",
"publisher": "FDA",
"sourceClass": "fda_guidance",
"accessedAt": "2026-06-01",
"status": "verified",
"access": "sample",
"originalUrl": "https://www.fda.gov/media/166215/download",
"publicationDate": "2024-10-01",
"transformChain": [],
"provenanceNotes": "Guidance source; verify local applicability before relying on exact obligations.",
"url": "https://www.fda.gov/media/166215/download"
}
],
"evidence": [
{
"id": "E1",
"sourceId": "S1",
"claimIds": [
"C1"
],
"summary": "Extracted signal: ICH E6(R3) modernizes GCP principles and Annex 1 around trial quality, proportionality and records. Report inference: AI-enabled trial operations should preserve quality and record evidence before claiming productivity value.",
"status": "verified",
"confidence": 0.86,
"access": "sample"
},
{
"id": "E2",
"sourceId": "S2",
"claimIds": [
"C1"
],
"summary": "FDA DHT guidance gives recommendations for remotely acquiring data from clinical-trial participants, including suitability, verification, validation and data usability.",
"status": "verified",
"confidence": 0.87,
"access": "sample"
},
{
"id": "E3",
"sourceId": "S3",
"claimIds": [
"C1"
],
"summary": "EMA guidance on computerized systems and electronic data in clinical trials sets expectations for electronic records, systems, data integrity and service-provider oversight.",
"status": "verified",
"confidence": 0.86,
"access": "sample"
},
{
"id": "E4",
"sourceId": "S4",
"claimIds": [],
"summary": "ClinicalTrials.gov modernization updates affect data ingest, registry interfaces and trial-results workflow evidence.",
"status": "verified",
"confidence": 0.82,
"access": "sample"
},
{
"id": "E5",
"sourceId": "S5",
"claimIds": [],
"summary": "FDA AI drug-development guidance applies when AI output supports regulatory decisions about safety, effectiveness or quality.",
"status": "verified",
"confidence": 0.86,
"access": "sample"
},
{
"id": "E11",
"sourceId": "S11",
"claimIds": [
"C1"
],
"summary": "FDA's October 2024 guidance treats electronic systems, records and signatures in clinical investigations as regulated controls when systems create, modify, maintain, archive, retrieve or transmit clinical-investigation records.",
"status": "verified",
"confidence": 0.88,
"access": "sample"
}
],
"claims": [
{
"id": "C1",
"statement": "Trial and regulatory agents should be governed by protocol-versioned handoff records because electronic data, remote acquisition and computerized systems are already regulated work objects.",
"confidence": 0.87,
"evidenceIds": [
"E1",
"E2",
"E3"
],
"access": "sample"
}
],
"colophon": {
"checkedAt": "2026-06-01",
"latestRevisionAt": "2026-06-01T00:00:00Z",
"reviewStandard": "expert_human_reviewed",
"kinetics": {
"speed": "moderate",
"impact": 0.89,
"momentum": 0.83,
"businessImpact": "Trial and regulatory agents earn budget when they reduce rework in named handoffs across matching, monitoring, submissions and agency response.",
"rateOfChange": "Protocol amendments, endpoint data streams and registry or submission defects are raising the proof burden for each handoff.",
"from": "isolated trial automation and document drafting",
"toward": "accepted trial and regulatory records with source data, reviewer action and rework telemetry"
},
"watch": [],
"gapAnalysis": "Longitudinal trial-operations telemetry linking site burden, monitoring findings, EDC query closure, registry defects, safety-narrative quality, submission QC findings, agency rework and inspection-readiness evidence."
},
"body": {
"sections": [
{
"id": "executive-summary",
"title": "Executive summary",
"access": "sample",
"claimIds": [
"C1"
],
"evidenceIds": [
"E1",
"E3",
"E11",
"E2",
"E5"
],
"blocks": [
{
"id": "executive-summary-narrative",
"evidenceIds": [
"E1",
"E3",
"E11",
"E2",
"E5"
],
"type": "section_narrative",
"lead": "Clinical-trial AI budget should be tied to defect closure in named handoffs, not drafting speed: fewer poor matches, open EDC queries, missing eTMF records, registry defects, endpoint-data gaps, safety-narrative QC findings and agency-response rework.",
"body": [
"The hidden problem is defect movement across protocol versions, source data and trial records. A task agent is valuable only when poor matches, open EDC queries, missing eTMF evidence [E1, E3], registry defects, endpoint-data gaps, safety-narrative QC findings or agency-response rework fall in the sponsor's named systems.",
"The trap is speed without defect removal. Matching, monitoring, data-review, registry, safety-narrative or agency-response agents can make teams faster while leaving source data, audit trail, reviewer action and essential-document status out of sync. FDA electronic-record and eSource controls make that record boundary explicit [E11, E12].",
"The operating denominator is defect closure: enrolled-quality matches, closed queries, usable endpoint records, fewer registry corrections, fewer QC findings and less agency rework. Price the lane by defects, reviewer minutes, cycle time and inspection-readiness gaps before volume expansion.",
"The first production lane should be a workflow where the outcome is already visible in the sponsor's systems: query closure, registry/results submission, protocol-amendment evidence, endpoint data usability or agency-response QC. Drafting speed counts only after the handoff preserves source, protocol version, reviewer action and retained evidence."
],
"detail": [
"Make the handoff packet a contract deliverable: protocol version, source record ID, data origin, target system, reviewer action, audit trail, validation or credibility evidence, essential-document link, defect metric and rework reason.",
"Scale only when the agent reduces queries, missing records, registry defects, QC findings or agency rework across trial and regulatory operations. Drafting speed alone is operational convenience; board-level value requires fewer defects."
]
},
{
"id": "board-decision-table",
"title": "The buying decision",
"evidenceIds": [
"E1",
"E3",
"E11",
"E2",
"E5"
],
"type": "table",
"columns": [
{
"key": "question",
"label": "Question",
"align": "left"
},
{
"key": "answer",
"label": "Answer",
"align": "left"
},
{
"key": "move",
"label": "Action",
"align": "left"
}
],
"rows": [
{
"question": "What is the object of approval?",
"answer": "The record for one lane: enrolled-quality match, closed EDC query or inspection-ready eTMF document [E11, E12], registry/results submission [E13], endpoint usability record [E2, E5], safety narrative QC [E18] or agency-response package [E19].",
"move": "Require source data, protocol version, reviewer action, validation or credibility evidence, essential-document status and rework telemetry for that record."
},
{
"question": "Which lane goes first?",
"answer": "A high-volume query, registry/results, protocol-amendment, endpoint-data or agency-response workflow with visible defects and rework.",
"move": "Baseline cycle time, QC findings, open queries, review minutes, submission defects, agency questions and inspection-readiness gaps."
},
{
"question": "What remains blocked?",
"answer": "Autonomous eligibility, endpoint, query-closure, submission or safety-narrative decisions without source, validation, reviewer and essential-document evidence.",
"move": "Keep the agent in suggestion or drafting mode until the accepted-record evidence proves the workflow can survive inspection."
}
]
}
]
},
{
"id": "what-changed",
"title": "What changed",
"access": "sample",
"dek": "Public evidence is now structured enough to define private approval tests.",
"claimIds": [
"C1"
],
"evidenceIds": [
"E1",
"E2",
"E4",
"E5",
"E11"
],
"blocks": [
{
"id": "what-changed-narrative",
"evidenceIds": [
"E1",
"E2",
"E4",
"E5",
"E11"
],
"type": "section_narrative",
"lead": "Source-to-record drift is the pressure: protocol amendments, remote endpoint data, registry updates, submission responses and agency questions now move faster than manual reconciliation.",
"body": [
"Clinical-trial value disappears when AI-generated speed moves defects to sites, monitors or regulatory reviewers. The buyer needs protocol version, data origin, audit trail, reviewer action and essential-document evidence before AI changes a matching, monitoring, data-review, submission or safety-narrative lane; GCP and DHT guidance make those controls source-grade rather than optional [E1, E2].",
"Choose one artefact family, baseline defects and rework, require source traceability, and expand only when records improve without weakening inspection readiness.",
"For clinical-trial and regulatory workflows, the approval record has to connect source data, accepted output, reviewer action, exception path, audit trail and retained regulatory evidence before volume or staffing claims matter."
]
},
{
"id": "trigger-table",
"title": "Triggers that change approval timing",
"evidenceIds": [
"E1",
"E2",
"E4",
"E11",
"E5"
],
"type": "table",
"columns": [
{
"key": "trigger",
"label": "Trigger",
"align": "left"
},
{
"key": "why_now",
"label": "Why it matters",
"align": "left"
},
{
"key": "buyer_action",
"label": "Decision use",
"align": "left"
}
],
"rows": [
{
"trigger": "ICH E6(R3)",
"why_now": "GCP modernization reinforces quality-by-design and proportionate control [E1].",
"buyer_action": "Map AI workflows to source data, essential documents and quality risk."
},
{
"trigger": "FDA DHT guidance",
"why_now": "Remote data and digital endpoints need suitability, validation and data-usability evidence [E2].",
"buyer_action": "Require DHT and endpoint validation evidence where agents use remote data."
},
{
"trigger": "ClinicalTrials.gov modernization",
"why_now": "ClinicalTrials.gov modernization affects data ingest, registry interfaces and trial-results workflow evidence [E4]. 42 CFR Part 11 defines registration and results obligations, while FDA enforcement materials show remediation exposure [E13, E14].",
"buyer_action": "Separate registry-interface changes from legal obligations, corrections and enforcement risk in regulatory ops agents."
},
{
"trigger": "FDA electronic-systems/eSignature and eSource controls",
"why_now": "AI-touched clinical-investigation records need data-originator, audit-trail, signature and inspection-availability evidence [E11, E12].",
"buyer_action": "Classify each agent by whether it creates, modifies, maintains, archives, retrieves or transmits regulated records."
},
{
"trigger": "Structured protocol standards",
"why_now": "M11 makes protocol structure a computable diligence surface [E15], with CDISC DDF and HL7 Vulcan adding data-flow and FHIR implementation routes [E16, E17].",
"buyer_action": "Prefer agents that consume structured protocol objects before accepting PDF-only parsing."
},
{
"trigger": "FDA AI drug-development guidance",
"why_now": "AI outputs that support regulatory decisions need context-of-use credibility evidence [E5].",
"buyer_action": "Classify any endpoint, safety, effectiveness, quality or agency-response output by evidence burden."
}
]
},
{
"id": "route-definition-callout",
"title": "Route definition",
"evidenceIds": [
"E11"
],
"type": "callout",
"tone": "neutral",
"body": "Route means the approved path from work to accepted output: the source set, data boundary, model or vendor channel, tools, reviewer, evidence record and reapproval trigger that make an AI result usable."
}
]
},
{
"id": "decision-map",
"title": "Decision map",
"access": "sample",
"dek": "Workflow approval changes by authority, source boundary and proof burden.",
"claimIds": [
"C1"
],
"evidenceIds": [
"E11"
],
"blocks": [
{
"id": "decision-map-narrative",
"evidenceIds": [
"E11"
],
"type": "section_narrative",
"lead": "Fund clinical-trial and regulatory agents only when they reduce rework in a named trial or regulatory handoff.",
"body": [
"The decision map should start with a named trial or regulatory handoff from source event to accepted EDC, eTMF, registry, submission or agency-response record: what source record is read, what output is drafted, who approves it, where it is stored and what event forces reapproval.",
"A system can pass a low-risk support test and still fail production work: source evidence, accepted output, integration state, exception handling, reviewer burden and downstream rework have to hold together.",
"The useful vendor question is whether the system can make the named task inspectable, reversible and measurable inside the operating record."
]
},
{
"id": "route-selection-table",
"title": "Workflow selection",
"evidenceIds": [
"E11"
],
"type": "table",
"columns": [
{
"key": "route",
"label": "Workflow",
"align": "left"
},
{
"key": "accepted_output",
"label": "Accepted work",
"align": "left"
},
{
"key": "gate",
"label": "Approval gate",
"align": "left"
},
{
"key": "buyer_rule",
"label": "Approval rule",
"align": "left"
}
],
"rows": [
{
"route": "Trial matching",
"accepted_output": "Enrolment-ready candidate list with inclusion, exclusion and source-record evidence.",
"gate": "EHR source and recruitment workflow [E10]. Patient-selection and protocol criteria evidence [E6, E15].",
"buyer_rule": "Measure screened-to-enrolled quality, not just match volume."
},
{
"route": "Protocol and site operations",
"accepted_output": "Protocol-amendment task, feasibility answer or site document routed to the named owner.",
"gate": "Protocol version, role, system of record and reviewer approval.",
"buyer_rule": "Block write-back without version and audit evidence."
},
{
"route": "Monitoring and data review",
"accepted_output": "Closed EDC query or monitor-reviewed risk signal with source-data linkage.",
"gate": "Source-data verification, audit trail, monitor review and closure evidence [E11, E12].",
"buyer_rule": "Use risk-based monitoring metrics before staff reduction."
},
{
"route": "Submission and agency response",
"accepted_output": "QC'd registry update [E13], eCTD-ready agency response [E19] or safety narrative [E18] with source citations.",
"gate": "Source document, regulatory owner and QC, with registry record [E13] or eCTD package [E19] when those routes apply.",
"buyer_rule": "Treat as regulated evidence when the output supports a filing or agency interaction."
}
]
},
{
"id": "workflow-authority-matrix",
"title": "Write authority changes the proof burden",
"caption": "Use the matrix to decide what proof is required before each workflow becomes accepted work.",
"evidenceIds": [
"E11"
],
"type": "visual_matrix",
"columns": [
"Source path",
"Reviewer gate",
"System action",
"Retest trigger"
],
"rows": [
{
"label": "Trial matching",
"note": "Enrolment-ready candidate list with inclusion, exclusion and source-record evidence.",
"cells": [
{
"label": "Source named",
"detail": "EHR source and recruitment workflow [E10]. Patient-selection and protocol criteria evidence [E6, E15].",
"tone": "info",
"strength": "medium"
},
{
"label": "Human gate",
"detail": "Measure screened-to-enrolled quality, not just match volume.",
"tone": "blocked",
"strength": "gate"
},
{
"label": "Accepted work",
"detail": "Enrolment-ready candidate list with inclusion, exclusion and source-record evidence.",
"tone": "success",
"strength": "high"
},
{
"label": "Reapproval",
"detail": "Retest when policy, workflow, model, data access or system write rights change.",
"tone": "warning",
"strength": "medium"
}
]
},
{
"label": "Protocol and site operations",
"note": "Protocol-amendment task, feasibility answer or site document routed to the named owner.",
"cells": [
{
"label": "Source named",
"detail": "Protocol version, role, system of record and reviewer approval.",
"tone": "info",
"strength": "medium"
},
{
"label": "Human gate",
"detail": "Block write-back without version and audit evidence.",
"tone": "blocked",
"strength": "gate"
},
{
"label": "Accepted work",
"detail": "Protocol-amendment task, feasibility answer or site document routed to the named owner.",
"tone": "success",
"strength": "high"
},
{
"label": "Reapproval",
"detail": "Retest when policy, workflow, model, data access or system write rights change.",
"tone": "warning",
"strength": "medium"
}
]
},
{
"label": "Monitoring and data review",
"note": "Closed EDC query or monitor-reviewed risk signal with source-data linkage.",
"cells": [
{
"label": "Source named",
"detail": "Source-data verification, audit trail, monitor review and closure evidence [E11, E12].",
"tone": "info",
"strength": "medium"
},
{
"label": "Human gate",
"detail": "Use risk-based monitoring metrics before staff reduction.",
"tone": "blocked",
"strength": "gate"
},
{
"label": "Accepted work",
"detail": "Closed EDC query or monitor-reviewed risk signal with source-data linkage.",
"tone": "success",
"strength": "high"
},
{
"label": "Reapproval",
"detail": "Retest when policy, workflow, model, data access or system write rights change.",
"tone": "warning",
"strength": "medium"
}
]
},
{
"label": "Submission and agency response",
"note": "QC'd registry update [E13], eCTD-ready agency response [E19] or safety narrative [E18] with source citations.",
"cells": [
{
"label": "Source named",
"detail": "Source document, regulatory owner and QC, with registry record [E13] or eCTD package [E19] when those routes apply.",
"tone": "info",
"strength": "medium"
},
{
"label": "Human gate",
"detail": "Treat as regulated evidence when the output supports a filing or agency interaction.",
"tone": "blocked",
"strength": "gate"
},
{
"label": "Accepted work",
"detail": "QC'd registry update [E13], eCTD-ready agency response [E19] or safety narrative [E18] with source citations.",
"tone": "success",
"strength": "high"
},
{
"label": "Reapproval",
"detail": "Retest when policy, workflow, model, data access or system write rights change.",
"tone": "warning",
"strength": "medium"
}
]
}
],
"legend": [
{
"label": "Private eval can start here",
"tone": "success",
"strength": "high"
},
{
"label": "Requires named owner or reviewer",
"tone": "warning",
"strength": "medium"
},
{
"label": "Hard approval gate before scale",
"tone": "blocked",
"strength": "gate"
}
]
}
]
},
{
"id": "signature-proof",
"title": "Signature proof",
"access": "locked",
"dek": "The decisive proof is whether the workflow survives evidence, audit and rework.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "signature-proof-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "provider-workflow-landscape",
"title": "Provider lanes",
"access": "locked",
"dek": "Providers should be compared by workflow authority.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "provider-workflow-landscape-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "use-case-route-selection",
"title": "Workflow selection",
"access": "locked",
"dek": "Production starts with the lane where output can be accepted or rejected visibly.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "use-case-route-selection-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "evidence-and-benchmarks",
"title": "Evidence fit",
"access": "locked",
"dek": "Public evidence maps to local accepted work.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "evidence-and-benchmarks-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "private-eval-design",
"title": "Private eval design",
"access": "locked",
"dek": "Public evidence chooses the tests; local cases decide production.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "private-eval-design-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "risks-and-controls",
"title": "Risks and controls",
"access": "locked",
"dek": "The main risk is ungoverned action.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "risks-and-controls-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "operating-model",
"title": "Operating model",
"access": "locked",
"dek": "Production ownership crosses clinical, technical, compliance and finance teams.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "operating-model-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "economics",
"title": "Economics",
"access": "locked",
"dek": "Price the accepted work.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "economics-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "implementation-signals",
"title": "Public claim tests",
"access": "locked",
"dek": "Vendor pages seed diligence; local telemetry supplies operating proof.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "implementation-signals-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "vendor-directory",
"title": "Diligence directory",
"access": "locked",
"dek": "Representative vendors and platform RFI anchors to include in diligence.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "vendor-directory-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "recommended-next-steps",
"title": "Recommended next steps",
"access": "locked",
"dek": "A practical workflow can be approved in phases without pretending the whole market is ready.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "recommended-next-steps-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "known-unknowns",
"title": "Known unknowns",
"access": "locked",
"dek": "These gaps should shape diligence rather than delay all buying.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "known-unknowns-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "source-ledger",
"title": "Source ledger",
"access": "locked",
"dek": "Primary public sources and evidence rows behind the workflow analysis.",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "source-ledger-locked",
"title": "Locked section",
"evidenceIds": [],
"type": "callout",
"tone": "locked",
"body": "Purchase or subscribe to unlock this section."
}
]
},
{
"id": "glossary",
"title": "Glossary",
"access": "sample",
"claimIds": [],
"evidenceIds": [],
"blocks": [
{
"id": "glossary-table",
"title": "Terms used in this report",
"caption": "Definitions are reader aids, not separate evidence claims.",
"evidenceIds": [],
"type": "table",
"columns": [
{
"key": "term",
"label": "Term",
"align": "left"
},
{
"key": "meaning",
"label": "Plain meaning",
"align": "left"
}
],
"rows": [
{
"term": "Route",
"meaning": "The approved path from work to accepted output: source set, data boundary, model or vendor channel, tools, reviewer, evidence record and reapproval trigger."
}
]
}
]
}
]
}
},
"gap_analysis": "Longitudinal trial-operations telemetry linking site burden, monitoring findings, EDC query closure, registry defects, safety-narrative quality, submission QC findings, agency rework and inspection-readiness evidence.",
"kinetics": {
"speed": "moderate",
"impact": 0.89,
"momentum": 0.83,
"businessImpact": "Trial and regulatory agents earn budget when they reduce rework in named handoffs across matching, monitoring, submissions and agency response.",
"rateOfChange": "Protocol amendments, endpoint data streams and registry or submission defects are raising the proof burden for each handoff.",
"from": "isolated trial automation and document drafting",
"toward": "accepted trial and regulatory records with source data, reviewer action and rework telemetry"
},
"watch_signals": [],
"sample_findings": [
"The budget unit is a named handoff: accepted trial match, closed query, registry defect, submission QC finding or agency-response rework."
]
}
```